Journal of Molecular and Cellular Cardiology 49 (2010) 836–840

Contents lists available at ScienceDirect

Journal of Molecular and Cellular Cardiology

journal homepage: www.elsevier.com/locate/yjmcc

Original article

Partial rescue of the *Tbx1* mutant heart phenotype by *Fgf8*: Genetic evidence of impaired tissue response to Fgf8

Francesca Vitelli [a,1], Gabriella Lania [b,1], Tuong Huynh [a], Antonio Baldini [a,b,*]

[a] Institute of Biosciences and Technologies, Texas A&M University, Houston, TX, USA
[b] Institute of Genetics and Biophysics of the National Research Council, Naples, Italy

ARTICLE INFO

Article history:
Received 16 May 2010
Received in revised form 11 August 2010
Accepted 24 August 2010
Available online 31 August 2010

Keywords:
T-box
Cardiac outflow tract septation
DiGeorge syndrome
FGF signaling pathway
Cardiac progenitors

ABSTRACT

Tbx1 is the candidate gene of DiGeorge syndrome and is required in humans and mice for the development of the cardiac outflow tract (OFT) and aortic arch arteries. Loss of function mutants present with reduced cell proliferation and premature differentiation of cardiac progenitor cells of the second heart field (SHF). Tbx1 regulates *Fgf8* expression hence the hypothesis that the proliferation impairment may contribute to the heart phenotype of mutants. Here we show that forced *Fgf8* expression modifies and partially rescues the OFT septation defects of *Tbx1* mutants but only if there is some residual expression of *Tbx1*. This genetic experiment suggests that Tbx1, directly or indirectly, affects tissue response to Fgf8. Indeed, $Tbx1^{-/-}$ mouse embryonic fibroblasts were unable to respond to Fgf8 added to the culture media and showed defective response of Erk1/2 and Rsk1. Our data suggest a coordinated pathway modulating Fgf8 ligand expression and tissue response to it in the SHF.

1. Introduction

Tbx1 is T-box transcription factor required for the development of several organs, including sections of the heart. Haploinsufficiency of *TBX1* can cause DiGeorge/Velocardiofacial syndrome, often associated with congenital heart disease. Mouse mutants recapitulate most of the human syndrome phenotype. *Tbx1* expression in the mesoderm, and, in particular, in the mesoderm expressing the cardiogenic transcription factor *Nkx2.5*, is required for the elongation and septation of the cardiac outflow tract as well as for the septation of the ventricles [1]. Expression analyses and cell fate mapping established that *Tbx1* is expressed in the second heart field (SHF), which is a cardiac progenitor cell (CPC) population that migrates into the cardiac outflow tract (OFT), right ventricle and part of the atria. We have shown that *Tbx1* is expressed in tri-potent heart progenitors and, in these cells, it modulates positively cell proliferation and inhibits differentiation [2]. Thus, the molecular pathway(s) regulated by Tbx1 in CPCs could be exploited for the expansion of cardiac stem cells in future applications of regenerative medicine. Therefore, it is important to define the mechanisms effects its functions in CPCs and thus define the molecular players. There are at least two mechanisms that appear relevant to a role of Tbx1 in cell proliferation. One is the recently described mechanism of Smad1–Tbx1 interaction [3] that leads to inhibition of Smad1 signaling, which inhibits proliferation in the SHF [4]. Another is transcriptional regulation of *Fgf8*, a ligand of the fibroblast growth factor signaling that has, among other functions, mitogenic activity. Although *Tbx1* and *Fgf8* interact genetically [5], forced expression of *Fgf8* in the *Tbx1*-expression domain is insufficient to rescue the main phenotypic abnormalities of $Tbx1^{-/-}$ mutants, such as the heart phenotype [6]. However, forced expression of *Fgf8* in *Tbx1*-expressing cells is capable of partially rescue the severe thyroid phenotype, which is a cell non-autonomous consequence of *Tbx1* loss [7]. This finding and the availability of new mutant alleles have encouraged us to revisit the role of *Tbx1* in FGF signaling. Here we show that forced expression of *Fgf8* in mice that express a small dose of *Tbx1* mRNA rescues partially the heart phenotype, thus we hypothesized that *Tbx1* is necessary to respond to Fgf8. This hypothesis was successfully tested in a tissue culture model.

2. Materials and methods

In this work we used the following mouse lines previously described: $Tbx1^{Cre}$ [8], $Tbx1^{neo2}$ [9], $Tbx1^{fgf8}$ [6], $Fgf8^{fl/fl}$ and $Fgf8^{+/-}$ [10]. Phenotypic analysis was carried out by direct examination of dissected embryos and by histological analyses.

Primary mouse embryonic fibroblasts (MEFs) were isolated from individual $Tbx1^{-/-}$, $Tbx1^{neo2/-}$ and wild-type embryos at E13.5. To this hand, the internal organs, head, tail and limbs were removed. Cells were cultured in Dulbecco's modified Eagle's medium with 20% FBS and 1% NEAA, and used for a maximum of 4 passages. We derived and tested 3 wild type, 5 $Tbx1^{-/-}$ and 2 $Tbx1^{neo2/-}$ MEF lines, each derived from individual embryos.

* Corresponding author. Institute of Genetics and Biophysics CNR, Via Pietro Castellino 111, 80131 Napoli, Italy.
E-mail address: baldini@igb.cnr.it (A. Baldini).
[1] FV and GL have contributed equally to this work.

0022-2828/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.yjmcc.2010.08.023

Fgf8 treatment was carried out using recombinant Fgf8b (R&D) at 50 μg/ml along with 100 ng/ml of heparin (Sigma) for 5, 10 or 15 min.

Quantitative real time PCR was performed using reverse-transcribed total RNA from MEFs or whole embryos, using SYBR green and an Applied Biosystem 7900H machine, with the following primers: *Etv4* F-cagcaggaagccaccact, R-gggggagtcataggcactg; *Etv5* F-gcagtttgtccca-gattttca, R-gcagctcccgtttgatctt; *Rsk1* F-ttcacacggctctcaaagg, R-ccagct-cagccaggtaaaac. *Tbx1*: E3/E4-F: ctgaccaataacctgctggatga, E3/E4-R-ggctgatatctgtgcatggagtt. Relative quantification was calculated by the ΔΔCt method.

Western blotting analyses were performed using total protein extracts from MEF cells. The antibodies were purchased from Millipore (pRsk1), SantaCruz (Erk1/2, Crkl, Frs2α, Rsk1), Cell Signaling Technology, Inc (p44/42, pErk1/2), Abcam (Actin), and Sigma (Tubulin).

3. Results and discussion

3.1. Loss of Fgf8 in the Tbx1 domain causes Tbx1$^{-/-}$-like OFT septation defects

Using a tamoxifen-inducible *Tbx1*-cre (*Tbx1*^{mcm}) driver, we have shown that *Fgf8* dosage reduction in conditional mutants enhances the *Tbx1* haploinsufficiency phenotype at the level of aortic arch defects [6], but we could not find OFT defects. In addition, Brown et al. [11] using a *Tbx1* promoter-enhancer construct as the transgenic Cre driver, observed various types of OFT defects in *Fgf8* conditional mutants, but they did not report truncus arteriosus communis (TAC) the typical OFT defect observed in *Tbx1*$^{-/-}$ mutants. Thus, we decided to repeat the experiment using our latest Cre knock-in driver, *Tbx1*^{Cre}, which induces robust recombination and is expressed in the endogenous *Tbx1* domain [8]. RNA *in situ* hybridization with an *Fgf8*-deletion specific probe [10] at E9 showed undetectable or very low levels of *Fgf8*-expression in the pharyngeal region of *Tbx1*$^{Cre/+}$; *Fgf8*$^{fl/-}$ embryos compared to controls while other domains such as the fronto-nasal process and limb bud showed robust expression (Fig. 1A, B). Analysis of the OFT phenotype in E18.5 *Tbx1*$^{Cre/+}$;*Fgf8*$^{fl/-}$ embryos revealed the presence of truncus arteriosus communis (TAC) in 67% (10/15) of them. In 5 of the 10 embryos with TAC, the defect was partial (Fig. 1E–J), while in the remainder, the defect was complete i.e. total lack of septation, similarly to *Tbx1*$^{-/-}$ mutants. In all conditional mutants with TAC, the truncal valve maintained its continuity to the mitral valve, indicating that the alignment of the OFT with the ventricles is less defective in these mutants than in *Tbx1*$^{-/-}$ animals. In addition, in all embryos, the TAC was positioned above the inter-ventricular septum straddling a ventricular septal defect (VSD) (Fig. 1H–I). In contrast, in *Tbx1*$^{-/-}$ mutants, the TAC is positioned on the right ventricle. Thus, conditional ablation of *Fgf8* in the *Tbx1* domain interrupts both conal and truncal septation, but rotation and alignment of the OFT are only mildly affected. Overall, these data demonstrate that the loss of expression of *Fgf8* in *Tbx1*-expressing cells causes OFT developmental abnormalities similar to those caused by loss of *Tbx1*, at least in a *Tbx1*$^{+/-}$ background.

3.2. Fgf8 rescue of OFT septation defects of Tbx1 mutants requires a small amount of functional Tbx1

The *Tbx1*^{Fgf8} allele is null for *Tbx1* and expresses an *Fgf8* cDNA in the *Tbx1* expression domain [6]. Despite the predicted importance of the loss of *Fgf8* expression in the pathogenesis of OFT septation defects of *Tbx1*$^{-/-}$ mutants, this allele did not modify these defects in *Tbx1*-null embryos [6]. Therefore, we considered the hypothesis that the complete absence of *Tbx1* may impair the cellular response to Fgf8. This hypothesis would also explain why the *Tbx1*^{Fgf8} allele could partially rescue the thyroid phenotype of *Tbx1*$^{-/-}$ mutants [7]. Indeed, Tbx1 is not expressed in the thyroid tissue, targeted by Fgf8, thus it cannot have any role in regulating response to Fgf8 in this tissue.

To address this hypothesis in vivo, we carried out rescue experiments in mice that express a low amount of *Tbx1* (per se insufficient to support normal development of the OFT), but perhaps sufficient to partially restore cellular response to Fgf8.

We used the *Tbx1*^{neo2} allele that expresses 15-20% of the WT *Tbx1* mRNA level [12]. *Tbx1*$^{neo2/-}$ animals show very similar cardiovascular defects as *Tbx1*$^{-/-}$ mutants, indicating that this low level of *Tbx1* expression is insufficient to modify significantly the OFT null phenotype [9,12]. We maintain the *Tbx1*^{Fgf8} allele in the *Tbx1*$^{Fgf8/Dp1}$ background, where *Dp1* is a segmental duplication of the *Tbx1* locus which rescues the high penetrance of aortic arch defects associated with the *Tbx1*^{Fgf8} allele [6]. *Tbx1*$^{Fgf8/Dp1}$ mice were crossed with *Tbx1*$^{neo2/+}$ mice, and the offspring examined at E18.5. In total, we have analyzed 97 embryos (18 *Tbx1*$^{Fgf8/neo2}$, 29 *Tbx1*$^{Fgf8/+}$, 19 *Tbx1*$^{neo2/Dp1}$, and 31 *Tbx1*$^{+/Dp1}$), of these, only *Tbx1*$^{Fgf8/neo2}$ and *Tbx1*$^{Fgf8/+}$ embryos presented with cardiovascular abnormalities. In particular, 19 *Tbx1*$^{Fgf8/+}$ embryos (66%) exhibited aortic arch artery abnormalities but no OFT defects (consistent with previously reported data (6)). All the 18 *Tbx1*$^{Fgf8/neo2}$ embryos presented with OFT defects (Fig. 2A–D"). These included TAC (10 embryos, 56%), double outlet right ventricle (DORV) (7 embryos, 39%) and transposition of the great arteries (TGA, 1 embryo or 6%). This phenotype represents a considerable improvement compared to the one observed in *Tbx1*$^{neo2/-}$ embryos. Indeed, the latter genotype is associated with 95% incidence of TAC [9,12], thus almost all embryos lack OFT septation. In contrast, only 56% of *Tbx1*$^{Fgf8/neo2}$ embryos lack OFT septation. We could no find any other phenotypic changes compared to the *Tbx1*$^{neo2/-}$ phenotype. To evaluate whether the partial phenotypic rescue may be caused by up-regulation of the *Tbx1*^{neo2} allele by Fgf8, we performed real time quantitative (qRT) PCR analysis on E9 embryos (Fig. 1K). The average relative expression level was not significantly different (19% for *Tbx1*$^{Fgf8/neo2}$ vs. 14% for *Tbx1*$^{neo2/-}$; $p = 0.07$ with 2-tailed T-test). These data support the hypothesis that reduced *Fgf8* expression in *Tbx1*$^{-/-}$ embryos contributes to the OFT septation phenotype and it also suggest that Tbx1 is required for tissue response to Fgf8.

3.3. Tbx1$^{-/-}$ cells do not respond normally to Fgf8

To support the above in vivo findings that suggest a requirement of *Tbx1* for normal response to Fgf8, we evaluated the response of cultured mouse embryonic fibroblasts (MEFs) from wild type and *Tbx1*$^{-/-}$ embryos, to recombinant Fgf8b protein added to the culture media. We measured the expression of two genes known to respond positively to Fgf8 treatment, *Etv4* (also known as *Pea3*) and *Etv5* (also known as *Erm*) [13]. qRT-PCR analysis on two independent wild type MEF lines revealed a robust response to Fgf8, while two independent *Tbx1*$^{-/-}$ lines did not show any significant response (Fig. 2E). Next, we tested the phosphorylation of Rsk1, a downstream component of FGF and other growth factors signaling pathways, responsible for relaying the signal to the nucleus. Results showed a robust response to Fgf8 in wild type MEF cell lines, but very low signal in mutant cells (Fig. 2F). Rsk1 is a phosphorylation target of the MAP kinase Erk1/2. Therefore, we tested the phosphorylation response of Erk1/2 to FGF8. Analogously to the results with Rsk1, we did not find any difference in Erk activation in mutant cells (Fig. 2G). We checked whether loss of *Tbx1* causes any difference in the expression of Rsk1 or Erk1/2. For the latter, we could not demonstrate any difference in expression (Fig. 2G). However, for Rsk1 we saw reduced expression in most cell lines analyzed (each from an individual embryo) at the protein level (Supplementary Fig. S1) and RNA level (Supplementary Fig. S2). However, even in the presence of near normal levels of Rsk1 protein, we could not detect any phosphorylation response to FGF8 in mutant MEFs (Supplementary Fig. S1, lanes 3-4). The observed variability may be due to the heterogeneous nature of the primary MEF cultures. We also tested whether Frs2α [14] and Crkl [15] proteins are expressed